Tiziana Life Sciences (TLSA) Receivables (2017 - 2022)

Tiziana Life Sciences has reported Receivables for 6 years, with the latest figure at -$858000.0 in Q4 2022.

• On a quarterly basis, Receivables fell 170.73% year-over-year to -$858000.0 in Q4 2022; TTM through Dec 2022 was -$858000.0, a 170.73% decrease from a year earlier, with the FY2022 full-year figure at $4.8 million, up 175.81% from the prior year.
• Receivables was -$858000.0 for Q4 2022 at Tiziana Life Sciences, down from $1.2 million in the prior quarter.
• The five-year high for Receivables was $1.2 million in Q4 2021, with the low at -$858000.0 in Q4 2022.
• Average Receivables over 5 years is $496194.7, with a median of $683250.6 recorded in 2020.
• The sharpest annual moves came in 2019 and 2022: Receivables surged 1421.38% in 2019, then plunged 170.73% in 2022.
• Over 5 years, Receivables stood at $612501.2 in 2018, then soared by 51.77% to $929579.1 in 2019, then fell by 18.89% to $754000.0 in 2020, then soared by 60.88% to $1.2 million in 2021, then slumped by 170.73% to -$858000.0 in 2022.
• The last three Receivables figures came in at -$858000.0 (Q4 2022), $1.2 million (Q4 2021), and $754000.0 (Q4 2020), per Business Quant data.